Key result
Oral administration of L-arginine increased antioxidant markers and decreased pro-oxidant markers and serum cholesterol in patients with ischemic myocardial syndromes.
Why the study?
Does oral L-arginine improve oxidant/antioxidant homeostasis in patients with acute angina or myocardial infarction?
Does oral L-arginine improve oxidant/antioxidant homeostasis in patients with acute angina or myocardial infarction?
Oral L-arginine supplementation may improve oxidant/antioxidant homeostasis and reduce serum cholesterol in patients with ischemic myocardial syndromes.
Hypothesis-generating for L-arginine in ischemic syndromes; prospective randomized trials needed before clinical adoption.
Administration of L-arginine has been shown to control ischemic injury by producing nitric oxide which dilates the vessels and thus maintains proper blood flow to the myocardium. In the present study attempt has been made to determine whether oral administration of L-arginine has any effect on oxidant/ antioxidant homeostasis in ischemic myocardial patients [represented by the patients of acute angina (AA) and acute myocardial infarction (MI)]. L-arginine has antioxidant and antiapoptotic properties, decreases endothelin-1 expression and improves endothelial function, thereby controlling oxidative injury caused during myocardial ischemic syndrome. Effect of L-arginine administration on the status of free radical scavenging enzymes, pro-oxidant enzyme and antioxidants viz. total thiols, carbonyl content and plasma ascorbic acid levels in the patients has been evaluated. We have observed that L-arginine administration (three grams per day for 15 days) resulted in increased activity of free radical scavenging enzyme superoxide dismutase (SOD) and increase in the levels of total thiols (T-SH) and ascorbic acid with concomitant decrease in lipid per-oxidation, carbonyl content, serum cholesterol and the activity of proxidant enzyme, xanthine oxidase (XO). These findings suggest that the supplementation of L-arginine along with regular therapy may be beneficial to the patients of ischemic myocardial syndromes.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2009) studied Ischemic myocardial syndromes (acute angina and acute myocardial infarction). L-arginine was evaluated on Oxidant/antioxidant homeostasis (free radical scavenging enzymes, pro-oxidant enzyme, and antioxidants). Oral administration of L-arginine increased antioxidant markers and decreased pro-oxidant markers and serum cholesterol in patients with ischemic myocardial syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: